Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8976958 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4TRPA1 | |
| Hydrochloric Acid SCHEMBL23524437 | 0.98 | TAAR1 (0.61) | TAAR1SLC18A2SIGMAR1SLC6A4TRPA1 | |
| Cadaverine Tartrate SCHEMBL9773333 | 0.83 | TAAR1 (0.50) | TAAR1SLC18A2SIGMAR1SLC6A4TRPA1 | |
| SCHEMBL16356133 | 0.83 | TRPA1 (0.52) | TAAR1SLC18A2SIGMAR1SLC6A4TRPA1 | |
| SCHEMBL10076448 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL178625 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL765297 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL4680337 | 0.79 | SIGMAR1 (0.66) | SIGMAR1SLC6A4TRPA1CYP2D6 | |
| SCHEMBL178533 | 0.78 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7316113 | 0.78 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-0186680-B1 | PHENYLISOPROPYLAMINE DERIVATIVE AND ITS PREPARATION | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1988-03-30 | — | — | EP | disclosed |
| CN-85104166-A | Preparation of new medicine and its preparation | — | 1986-11-26 | — | — | CN | disclosed |
| EP-0186680-A1 | PHENYLISOPROPYLAMINE DERIVATIVE AND ITS PREPARATION. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1986-07-09 | — | — | EP | disclosed |
| WO-1985005617-A1 | PHENYLISOPROPYLAMINE DERIVATIVE AND ITS PREPARATION | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1985-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | TAAR1 1451/4885SLC18A2 244/4885SIGMAR1 773/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | TAAR1 48/4885SLC18A2 11/4885SIGMAR1 2/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | TAAR1 370/4885SLC18A2 1819/4885SIGMAR1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.